哈米因通过DYRK1A介导的超活性RAS/MAPK抑制胰腺癌
Cen Liu1, Jinchai Qi1, Danyang Ye1
1Beijing University of Chinese Medicine, Beijing 102400, China.
Biochemical pharmacology
|August 31, 2025
概括
双特异性氨酸酸化调节激酶1A (DYRK1A) 在胰腺癌中调节KRAS G12D. 哈米因抑制DYRK1A,抑制瘤生长,并为KRAS G12D驱动的癌症提供新的治疗点.
科学领域:
- 癌症学
- 分子生物学
- 生物化学
背景情况:
- 在胰腺癌中,KRAS G12D突变很常见,导致瘤生长.
- 新兴的KRAS G12D抑制剂显示有效性,但面临耐药性,需要新的治疗策略.
- 识别新目标对于克服耐药性和改善PC治疗结果至关重要.
研究的目的:
- 研究双特异性氨酸酸化调节激酶1A (DYRK1A) 在PC中调节KRAS G12D活性中的作用.
- 探索哈米因 (HM) 作为一种潜在的治疗药物,针对PC中的DYRK1A.
- 阐明DYRK1A对KRAS G12D/MAPK路径调节的分子机制.
主要方法:
- 生物化学试验评估DYRK1A的酸酶活性及其对KRAS G12D-GTP水平的影响.
- 光局部化,双分子光补充 (Bi-FC) 和共免疫沉 (Co-IP) 来确认DYRK1A- KRAS G12D相互作用.
- 用RNA测序分析HM治疗引起的基因表达变化.
- 用于验证DYRK1A作为治疗点的Caenorhabditis elegans模型.
主要成果:
- DYRK1A抑制了KRAS G12D过度活化,证明了其在调节KRAS G12D水平方面的作用.
- 哈尔明 (HM) 被确定为DYRK1A的抑制剂,导致抑制KRAS G12D/ MAPK活动和减少PC细胞恶性病变.
- 证实了DYRK1A和KRAS G12D之间的直接相互作用,DYRK1A的激酶活性对KRAS G12D的激活至关重要.
- HM治疗降低了与RAS相关的通路基因,并显示了抑制PC细胞自的潜力.
- 在C. elegans中的DYRK1A同类 (mbk-1) 功能丧失突变抑制了KRAS G12D诱导的表型.
结论:
- 在激活KRAS G12D和促进PC进展方面,DYRK1A起着至关重要的作用.
- 通过抑制DYRK1A激酶活性来抑制RAS/ MAPK通路.
- 对于KRAS G12D驱动的胰腺癌,DYRK1A是一个有前途的治疗点.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
MAPK Signaling Cascades
6.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
The Ras Gene
6.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.4K


